OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to discuss the agency’s use of AI to speed up drug evaluations, Wired reported on Wednesday.
According to the report, OpenAI and the FDA have discussed a project called cderGPT, which seems to be an AI tool for the Center for Drug Evaluation (CDE). The CDE regulates over-the-counter and prescription drugs in the U.S. Associates from Elon Musk’s DOGE have reportedly been part of the talks as well.
Article Source
https://techcrunch.com/2025/05/07/openai-and-the-fda-are-reportedly-discussing-ai-for-drug-evaluations/
